University of Helsinki, Division of Pharmacology and Pharmacotherapy, Satakunta Hospital District, Unit of Neurology, Social Security Center of Pori, Hospital Services, Finland
Auto-generated profile, based on publicly available information
Juha Puustinen
University of Helsinki, Division of Pharmacology and Pharmacotherapy, Satakunta Hospital District, Unit of Neurology, Social Security Center of Pori, Hospital Services, Finland
Laboratory diagnosis of Lyme neuroborreliosis (LNB) is partly based on the detection of intrathecal Borrelia burgdorferi–specific antibody production (increased antibody index (AI)). However, AI can be negative in patients with early LNB and, conversely, can remain elevated for months after antibiotic treatment. Recent studies suggested that the chemokine CXCL13 in the cerebrospinal fluid (CSF) is a biomarker for active LNB. Also, CSF neopterin-level determination has been used to assess the degree of neuroinflammation in a wide variety of diseases.
Previous studies have found associations between the use of central nervous system medication and the risk of cognitive decline in the aged. Our aim was to assess whether the use of a single central nervous system (CNS) medication and, on the other hand, the combined use of multiple CNS medications over time are related to the risk of cognitive decline in an older (≥ 65 yrs) population that is cognitively intact at baseline.
22 May 2014 in British Journal of Clinical Pharmacology
There is evidence that the use of any psychotropic and the concomitant use of two or more benzodiazepines are related to an increased risk of fractures in old age. However, also controversial results exist. The aim was to describe associations between the use of a psychotropic drug, or the concomitant use of two or more of these drugs and the risk of fractures in a population aged 65 years or over.